Form 4: Bolt Biotherapeutics Director Acquires Stock Options

Bolt Biotherapeutics Director Kathleen LaPorte acquired stock options for 5,000 shares of common stock.

Summary

• Kathleen LaPorte, a Director at Bolt Biotherapeutics, Inc., acquired stock options on June 10, 2026.
• The options grant the right to buy 5,000 shares of common stock at an exercise price of $4.43 per share.
• These options are exercisable and expire on June 9, 2036.
• The shares subject to the option will vest on the earlier of June 9, 2027, or the day before the next annual stockholder meeting, contingent on continued service.
• The option will vest in full upon a change in control of the Issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard grant of stock options to a director, indicating alignment of interests, but does not contain new financial performance data.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The vesting schedule tied to service and potential change in control provides incentives for continued engagement and alignment with shareholder interests.

Risks

• The vesting of options is contingent on the Reporting Person's continuous service, implying a risk of forfeiture if service is not maintained.
• The option vesting is subject to a change in control, indicating potential future dilution or restructuring events.

Future Outlook

The acquisition of stock options by a director suggests a positive outlook on the company's future performance, as the value of these options is tied to the stock price.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the biotechnology sector to align executive incentives with long-term company growth and shareholder value.

Stakeholder Impact

• Shareholders: The acquisition of options by a director can be seen as a positive signal of commitment and alignment with shareholder interests.
• Employees: The vesting conditions tied to service reinforce the importance of employee retention and performance.
• Management: The option grant incentivizes management to drive company performance and increase shareholder value.

Next Steps

• The options will vest according to the specified schedule, contingent on continued service or a change in control.

Key Dates

Keywords

Bolt Biotherapeutics, Form 4, Stock Options, Director, Insider Trading, Equity, SEC Filing, BOLT